Table 1.
Univariate and multivariate analyses (Cox regression) for factors associated with OS in the 186 patients cohort.
| Univariate HR | 95% CI | p | Multivariate HR | 95% CI | p | |
|---|---|---|---|---|---|---|
| Age | ||||||
| <64 | 1 | <0.0001 | 1 | 0.005 | ||
| ≥ 64 | 2.01 | 1.48–2.86 | 1.65 | 1.16–2.34 | ||
| Sex | ||||||
| Female | 1 | 0.94 | ||||
| Male | 0.99 | 0.72–1.37 | ||||
| Diagnosis | ||||||
| Biopsy | 1 | 0.11 | ||||
| Surgery | 0.8 | 0.7–1.1 | ||||
| Karnofsky status | ||||||
| <70 | 1 | <0.0001 | 1 | <0.0001 | ||
| ≥ 70 | 0.23 | 0.16–0.33 | 0.25 | 0.17–0.37 | ||
| Bevacizumab use | ||||||
| No | 1 | 0.003 | 1 | 0.19 | ||
| Yes | 0.61 | 0.44–1.85 | 0.78 | 0.54–1.13 | ||
| CD8+ | ||||||
| <median | 1 | 0.0002 | 1 | 0.01 | ||
| >median | 0.47 | 0.32–0.72 | 0.59 | 0.39–0.91 | ||
| IL-17 | ||||||
| <6,000 /mm3 | 1 | 0.02 | 1 | 0.01 | ||
| >6,000 /mm3 | 1.56 | 1.07–2.78 | 1.65 | 1.11–2.46 | ||
| Foxp3 | ||||||
| <median | 1 | 0.038 | ||||
| >median | 0.62 | 1.05–2.5 | ||||
| CD163 | ||||||
| <median | 1 | 0.09 | ||||
| >median | 1.33 | 0.95–1.81 |